JP2013540119A5 - - Google Patents

Download PDF

Info

Publication number
JP2013540119A5
JP2013540119A5 JP2013530829A JP2013530829A JP2013540119A5 JP 2013540119 A5 JP2013540119 A5 JP 2013540119A5 JP 2013530829 A JP2013530829 A JP 2013530829A JP 2013530829 A JP2013530829 A JP 2013530829A JP 2013540119 A5 JP2013540119 A5 JP 2013540119A5
Authority
JP
Japan
Prior art keywords
oxo
carbonyl
spiro
tetrahydro
benzoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013530829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013540119A (ja
JP5824055B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/054119 external-priority patent/WO2012042433A1/en
Publication of JP2013540119A publication Critical patent/JP2013540119A/ja
Publication of JP2013540119A5 publication Critical patent/JP2013540119A5/ja
Application granted granted Critical
Publication of JP5824055B2 publication Critical patent/JP5824055B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013530829A 2010-09-30 2011-09-20 N1−ピラゾロスピロケトンアセチル−CoAカルボキシラーゼ阻害剤 Active JP5824055B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38810210P 2010-09-30 2010-09-30
US61/388,102 2010-09-30
PCT/IB2011/054119 WO2012042433A1 (en) 2010-09-30 2011-09-20 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS

Publications (3)

Publication Number Publication Date
JP2013540119A JP2013540119A (ja) 2013-10-31
JP2013540119A5 true JP2013540119A5 (enExample) 2014-10-16
JP5824055B2 JP5824055B2 (ja) 2015-11-25

Family

ID=44789556

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013530829A Active JP5824055B2 (ja) 2010-09-30 2011-09-20 N1−ピラゾロスピロケトンアセチル−CoAカルボキシラーゼ阻害剤

Country Status (15)

Country Link
US (8) US8859577B2 (enExample)
EP (1) EP2621493B1 (enExample)
JP (1) JP5824055B2 (enExample)
CA (1) CA2811033C (enExample)
CY (1) CY1118016T1 (enExample)
DK (1) DK2621493T3 (enExample)
ES (1) ES2602111T3 (enExample)
HR (1) HRP20161178T1 (enExample)
HU (1) HUE031616T2 (enExample)
LT (1) LT2621493T (enExample)
PL (1) PL2621493T3 (enExample)
PT (1) PT2621493T (enExample)
RS (1) RS55224B1 (enExample)
SI (1) SI2621493T1 (enExample)
WO (1) WO2012042433A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198483A1 (en) 2003-04-03 2004-10-07 Amaitis Lee M. System and method for betting on a subset of participants in an event
US8636571B2 (en) 2004-02-03 2014-01-28 Cantor Index, Llc System and method for managing select five horseracing bets
US9098883B2 (en) 2004-02-03 2015-08-04 Cantor Index, Llc Managing bets that select events and participants
US8318762B2 (en) 2008-05-28 2012-11-27 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
CN102695708B (zh) 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
RS55224B1 (sr) 2010-09-30 2017-02-28 Pfizer N1-pirazolospiroketon acetil-coa karboksilaza inhibitori
PT2632925E (pt) * 2010-10-29 2015-09-01 Pfizer Inibidores de n1/n2-lactama da acetil-coa carboxilase
RS54526B1 (sr) * 2011-04-22 2016-06-30 Pfizer Inc. Upotreba derivata pirazolospiroketona kao inhibitora acetil-coa karboksilaze
US8905832B2 (en) 2012-01-30 2014-12-09 Cfph, Llc Event wagering with group and/or in run options
US11055967B2 (en) 2014-03-26 2021-07-06 Cfph, Llc Event wagering with group and/or in run options
US20170178994A1 (en) * 2015-12-21 2017-06-22 Intel Corporation Integrated circuit package support structures
KR102579876B1 (ko) 2016-02-22 2023-09-18 삼성전자주식회사 반도체 패키지
CN110536682B (zh) * 2017-04-18 2023-01-06 基恩菲特公司 依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合
IL313710A (en) 2017-11-21 2024-08-01 Pfizer Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid
TWI707683B (zh) 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Glp-1受體促效劑及其用途
AU2019329884B2 (en) 2018-08-31 2022-01-27 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
EP4578460A3 (en) * 2019-05-20 2025-08-27 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
CN110183456A (zh) * 2019-07-11 2019-08-30 河南师范大学 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法
MX2022007105A (es) 2019-12-10 2022-07-11 Pfizer Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico.
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use
FI4097099T3 (fi) 2020-02-07 2024-07-30 Gasherbrum Bio Inc Heterosyklisiä glp-1-agonisteja
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Nafld/nashおよび関連疾患の処置のための組合せ
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
CA3176569A1 (en) 2020-03-27 2021-09-30 Pfizer Inc. Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
PL4143183T3 (pl) 2020-04-29 2026-03-02 Gasherbrum Bio, Inc. Heterocykliczni agoniści glp-1
AU2022336407A1 (en) 2021-08-31 2024-02-22 Pfizer Inc. Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2023228023A1 (en) 2022-05-23 2023-11-30 Pfizer Inc. Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
JP2025535295A (ja) 2022-10-18 2025-10-24 ファイザー・インク パタチン様ホスホリパーゼドメイン含有タンパク質3(pnpla3)修飾因子
JP2026501171A (ja) 2022-12-15 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド Glp-1アゴニスト活性を有する化合物の塩および固体形態
WO2025099561A1 (en) 2023-11-07 2025-05-15 Pfizer Inc. Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
WO2025224648A1 (en) 2024-04-26 2025-10-30 Pfizer Inc. Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
JP4104983B2 (ja) 2001-02-28 2008-06-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン−4受容体作動薬としてのアシル化ピペリジン誘導体
EP1478437B1 (en) 2002-02-27 2005-08-31 Pfizer Products Inc. Acc inhibitors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (ja) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
US20050267221A1 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
AP2006003768A0 (en) 2004-05-25 2006-10-31 Pfizer Prod Inc TetraazabenzoÄeÜazulene derivatives and analogs tehereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
BRPI0613427A2 (pt) 2005-07-19 2012-10-30 Merck & Co Inc composto ou seu sal ou éster, composição farmacêutica, agente terapêutico, e , uso do composto ou seu sal ou éster
US20100160255A1 (en) 2005-07-29 2010-06-24 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
DE102006016566B4 (de) 2005-09-22 2008-06-12 Beru Ag Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren
DE602006019304D1 (de) 2005-11-18 2011-02-10 Merck Sharp & Dohme Spirohydantoin-aryl-cgrp-rezeptorantagonisten
JP2009526868A (ja) 2006-02-15 2009-07-23 アボット・ラボラトリーズ 新規なアセチル−CoAカルボキシラーゼ(ACC)阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
AU2007326950B2 (en) 2006-11-29 2010-10-14 Pfizer Products Inc. Spiroketone acetyl-CoA carboxylase inhibitors
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
AU2008205642B2 (en) * 2007-01-12 2013-06-06 Msd K.K. Spirochromanon derivatives
JPWO2008102749A1 (ja) 2007-02-20 2010-05-27 武田薬品工業株式会社 複素環化合物
CA2683695C (en) 2007-04-12 2013-06-18 Pfizer Inc. 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
WO2009144555A1 (en) 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
US8318762B2 (en) 2008-05-28 2012-11-27 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
JP5501256B2 (ja) * 2008-07-04 2014-05-21 Msd株式会社 新規スピロクロマノンカルボン酸
EP2310015A4 (en) 2008-07-14 2011-10-26 Cropsolution Inc ACETYL-COENZYME-CARBOXYLASE MODULATORS AND METHODS OF USE THEREOF
CN102695708B (zh) 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
US20120225900A1 (en) 2009-11-10 2012-09-06 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
RS55224B1 (sr) * 2010-09-30 2017-02-28 Pfizer N1-pirazolospiroketon acetil-coa karboksilaza inhibitori
US20160034775A1 (en) 2014-08-02 2016-02-04 General Vault, LLC Methods and apparatus for bounded image data analysis and notification mechanism

Similar Documents

Publication Publication Date Title
JP2013540119A5 (enExample)
HRP20161178T1 (hr) N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
HRP20140025T1 (hr) N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
US11820781B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
US11591336B2 (en) Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
JP2010515734A5 (enExample)
AU2020276802A1 (en) Inhibitor containing bicyclic derivative, preparation method therefor and use thereof
US7173034B2 (en) Respiratory syncytial virus replication inhibitors
RU2016140338A (ru) Азаспиро производные в качестве антагонистов trpm8
US8299077B2 (en) Inhibitors of Bruton's tyrosine kinase
JP2021501220A5 (enExample)
JP2010506850A5 (enExample)
RU2018138050A (ru) Производные тиазолопиридина как агонисты gpr119
HRP20160539T1 (hr) Antagonisti trpv4
US9499548B2 (en) Inhibitors of bruton's tyrosine kinase
JP2012525395A5 (enExample)
US8742098B2 (en) Inhibitors of Bruton's tyrosine kinase
RU2017106742A (ru) Комбинированная терапия для лечения парамиксовируса
RU2008110915A (ru) Новые диазаспироалканы и их применение для лечения заболеваний, опосредованных ccr8
JP2022507724A (ja) 抗ウイルス剤としての官能化複素環
JP2013531684A5 (enExample)
JP2013542204A5 (enExample)
JP2012515789A5 (enExample)
JP2018505903A5 (enExample)
JP2013512953A5 (enExample)